These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12775634)

  • 1. Shared scheme for assessing drugs for multiple sclerosis: why are eyes tightly shut to considering causes other than autoimmunity?
    Chaudhuri A; Behan PO
    BMJ; 2003 May; 326(7400):1213. PubMed ID: 12775634
    [No Abstract]   [Full Text] [Related]  

  • 2. Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis.
    Napier JC; Francis R; Wright G
    BMJ; 2003 May; 326(7400):1212. PubMed ID: 12775633
    [No Abstract]   [Full Text] [Related]  

  • 3. The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.
    Detournay B
    Value Health; 2002; 5(1):1-2. PubMed ID: 11873378
    [No Abstract]   [Full Text] [Related]  

  • 4. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
    Clegg A; Bryant J; Milne R
    Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
    [No Abstract]   [Full Text] [Related]  

  • 5. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confusion over UK beta-interferon "trials".
    Dean M
    Lancet; 2001 Nov; 358(9293):1619. PubMed ID: 11716901
    [No Abstract]   [Full Text] [Related]  

  • 7. Funding of drug treatment of multiple sclerosis should not be delayed.
    Paty DW
    BMJ; 1997 Nov; 315(7116):1160-1. PubMed ID: 9374903
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.
    Bryant J; Clegg A; Milne R
    BMJ; 2000 May; 320(7247):1474-5; author reply 1475-6. PubMed ID: 10877569
    [No Abstract]   [Full Text] [Related]  

  • 9. Serono pays $44m to settle promotion of multiple sclerosis drug.
    Tanne JH
    BMJ; 2011 May; 342():d2922. PubMed ID: 21558361
    [No Abstract]   [Full Text] [Related]  

  • 10. [Disease-modifying treatment of MS--progress with complications].
    Fagius J
    Lakartidningen; 2003 Mar; 100(13):1164, 1167-8. PubMed ID: 12705166
    [No Abstract]   [Full Text] [Related]  

  • 11. [Interferon-beta in multiple sclerosis--who is going to be treated?].
    Aarli JA
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3114. PubMed ID: 10522472
    [No Abstract]   [Full Text] [Related]  

  • 12. Rebif offers another option for treating multiple sclerosis.
    Ryan M
    J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017
    [No Abstract]   [Full Text] [Related]  

  • 13. [Diagnostics and drug therapy of multiple sclerosis].
    Suomen Neurologinen Yhdistys ry
    Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?
    McNaughton H; Kayes N; McPherson K
    N Z Med J; 2006 Apr; 119(1232):U1939. PubMed ID: 16633398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta interferon and multiple sclerosis: why the fuss?
    Mumford CJ
    QJM; 1996 Jan; 89(1):1-3. PubMed ID: 8730337
    [No Abstract]   [Full Text] [Related]  

  • 16. Seeing injectable ms therapies differently: they are more similar than different.
    Johnson KP; Fox RJ; Arnold DL
    Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129
    [No Abstract]   [Full Text] [Related]  

  • 17. Glatiramer and suspected multiple sclerosis. No proven advantage.
    Prescrire Int; 2010 Aug; 19(108):160. PubMed ID: 20941852
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple sclerosis risk sharing scheme: a costly failure.
    Raftery J
    BMJ; 2010 Jun; 340():c1672. PubMed ID: 20522654
    [No Abstract]   [Full Text] [Related]  

  • 19. Time is money for nurse with MS. Interview by Esther Leach.
    Beeley D
    Nurs Times; 1999 Jul 7-13; 95(27):16-7. PubMed ID: 10524119
    [No Abstract]   [Full Text] [Related]  

  • 20. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.